Please login to the form below

Combination treatment

This page shows the latest Combination treatment news and features for those working in and with pharma, biotech and healthcare.

Janssen’s EGFR-targeting treatment regimen shows early benefit in lung cancer

The CHRYSALIS study investigators assessed the efficacy of the combination treatment using overall response rate (ORR) markers, as well as clinical benefit rate, duration of response and the safety profile of ... In a group of 45 patients who had

Latest news

BMS eyes approval for second Opdivo combo in kidney cancer

However, it has been facing competition from Merck &Co/MSD’s blockbuster checkpoint inhibitor Keytruda (pembrolizumab) plus Pfizer’s TKI Inlyta (ipilimumab) after the combination treatment won US Food and Drug ... combination treatment.
Lilly’s Olumiant combined with Gilead’s remdesivir hits the mark in COVID-19

The combination treatment hit the primary study endpoint of a reduction in recovery time. ... The combination treatment also met the secondary endpoint of comparing patient outcomes at day 15, using an ordinal eight-point scale ranging from fully
Janssen scores another expansion for new Darzalex combination in the US

The FDA has approved the expanded use of Darzalex (daratumumab) and dexamethasone in both once- and twice-weekly dosing regimens in combination with Kyprolis (carfilzomib), for the treatment of patients with ... It also has an approval for another
NICE recommends Roche’s Polivy for B-cell lymphoma

According to NICE, around 4, 800 people in England have DLBCL, with around 530 of those eligible for the new Polivy (polatuzumab vedotin) combination treatment. ... NICE said that the cost-effectiveness of the Polivy combination treatment was ‘very
BMS pays $475m for Dragonfly’s IL-12 immunotherapy programme

As well as testing the drug as a mono therapy, Dragonfly is also studying DF6002 in combination with PD-1 inhibiting treatment, such as BMS’ Opdivo (nivolumab). ... Dragonfly also signed a deal with Celgene, now owned by BMS, in 2017 and 2018 for a

More from news
Approximately 0 fully matching, plus 274 partially matching documents found.

Latest Intelligence

As COVID-19 takes over the world, biopharma fights back

A combination HIV treatment: AbbVie’s Kaletra. In an unprecedented move, AbbVie has suspended its patents on its combination HIV drug Kaletra, after it was identified as having potential against ... The combination drug was first included in Chinese
Deal Watch April 2016

Another deal worth pondering about is the $265m exclusive license by AstraZeneca (AZ) of the approved Zurampic (lesuranid) plus a fixed dose combination with allopurinol for treatment of gout. ... 85 . Dong A (SK). Tobira (US). Cross license. Evogliptin
Pharma deals in April 2015

No deal terms were disclosed. The initial development plan will look at the combination therapy as a potential treatment for NHL. . ... The treatment combines an antibody engineered to target CD19 with the cancer-killing agent maytansinoid.
Pharma deals during July 2014

Underscoring its strategy in focusing the business in the core areas, in July Baxter also announced the acquisition of AesRx, a private US company developing a phase II stage prophylactic treatment ... The acquisition of Almirall's respiratory business
Interview: AstraZeneca's Susan Galbraith

And again, matching drugs that work well together will be crucial going forward: “Combination treatment will be a critical component; how best to put these drugs together with other checkpoint inhibitors, ... This includes people with NSCLC who have a

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

Oncosec

body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; ... Results from recently completed
Marketing strategy in complex environments

The last few years have seen influential scientific advances, resulting in subtle shifts in how pharma tackles disease treatment. ... The treatment of aggressive diseases often benefits very noticeably from combination therapy, especially when involving

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Surviving cancer: a new era for patients: Now more than ever, a shift in perspective is needed...
Crisis? No problem!: Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?: First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....